Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
Atossa Therapeutics 公布了 40 毫克的 2 期 EVANGELINE 临床试验队列的数据
The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
EVANGELINE的研究正在评估（Z）-内氧芬作为一种新辅助疗法，用于治疗患有1级或2级雌激素受体阳性（ER+）/人类表皮生长因子受体2阴性（HER2-）的绝经前女性患者。Atossa是一家临床阶段的生物制药公司，在肿瘤学中尚未满足的重大医疗需求领域开发创新药物，重点是乳腺癌。